Sub menu
Open Close

What is Swelife?

Swelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s collaborative partners in healthcare, academia and industry. Swelife’s goal is to strengthen Swedish Life Science and improve public health. 

Swelife is a facilitator. By challenging obstacles and stimulating and supporting new national solutions for innovation, Swelife’s work is to contribute to these effects:

  • The knowledge and resources within life science in Sweden are utilised nationally through collaboration and coordination
  • Sweden offers good conditions for sustainable growth and international competitiveness in the life science sector
  • Citizens of Sweden have access to innovative, equal and personalised healthcare

Our vision

Life Science in Sweden will take the lead to generate world-class health and sustainable growth through innovation and collaboration.

Our mission

Swelife facilitates and accelerates innovation and collaboration in Life Science – from ideas to societal benefits.

Budget and support

More than 100 organisations from healthcare, academia and industry in Sweden currently support Swelife.


  • 2017: SEK 55 million from Vinnova (+SEK 55 million in co-financing)
  • 2016: SEK 40 million from Vinnova (+SEK 40 million in co-financing)
  • 2015: SEK 30 million from Vinnova (+SEK 30 million in co-financing)
  • 2014: SEK 9 million from Vinnova (+SEK 9 million in co-financing)
  • 2016–2019: some SEK 50 million from European structural funds (ERUF funding) through the Swedish Agency for Economic and Regional Growth.

The budget for 2018–2020 will be decided by Vinnova after an evaluation of Swelife in 2017.


Swelife was established in the summer of 2014 when the Diabetes Agenda and SILS (Sweden as an International Centre for Life Science) jointly applied to launch a so-called strategic innovation area (SIO). The idea was to gather the Life Science regions in Sweden under one common national research and innovation agenda.

The SIO on non-communicable diseases was approved in May 2014, changed its name to Swelife in the autumn, and in January 2015 included an additional agenda (PMC – Personalised Medicine Cancer).

For a competitive life science ecosystem in Sweden

With support from: